Search Result

Results for "

reperfusion

" in MCE Product Catalog:

By Targets:	Acyltransferase (1) Adenosine Receptor (1) Adrenergic Receptor (3) Akt (3) Amyloid-β (1) Antibiotic (1) Apoptosis (14) ATP Synthase (1) Autophagy (3) Calcium Channel (1) Cannabinoid Receptor (1) Caspase (5) CD38 (1) Complement System (1) Cytochrome P450 (1) Drug Metabolite (1) Dynamin (1) Elastase (4) Endogenous Metabolite (3) Ferroptosis (1) GlyT (1) HIF/HIF Prolyl-Hydroxylase (1) HIV (1) Influenza Virus (1) Insulin Receptor (1) Integrin (4) Interleukin Related (1) Leukotriene Receptor (5) MAP4K (1) Mitochondrial Metabolism (1) MMP (2) MyD88 (1) Na+/H+ Exchanger (NHE) (2) NF-κB (5) NO Synthase (4) NOD-like Receptor (NLR) (1) Opioid Receptor (1) p38 MAPK (2) PARP (4) Phosphodiesterase (PDE) (1) PKC (2) Potassium Channel (2) Prostaglandin Receptor (3) Protease Activated Receptor (PAR) (2) Reactive Oxygen Species (3) Reverse Transcriptase (1) RIP kinase (1) SARS-CoV (4) Sigma Receptor (2) Sirtuin (1) Telomerase (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) TRP Channel (2) Tyrosinase (1) Urotensin Receptor (2) VEGFR (1) α-synuclein (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (63) Endocrinology (2) Infection (5) Inflammation/Immunology (35) Metabolic Disease (6) Neurological Disease (17)

By Targets:

Acyltransferase (1)

Adenosine Receptor (1)

Adrenergic Receptor (3)

Akt (3)

Amyloid-β (1)

Antibiotic (1)

Apoptosis (14)

ATP Synthase (1)

Autophagy (3)

Calcium Channel (1)

Cannabinoid Receptor (1)

Caspase (5)

CD38 (1)

Complement System (1)

Cytochrome P450 (1)

Drug Metabolite (1)

Dynamin (1)

Elastase (4)

Endogenous Metabolite (3)

Ferroptosis (1)

GlyT (1)

HIF/HIF Prolyl-Hydroxylase (1)

HIV (1)

Influenza Virus (1)

Insulin Receptor (1)

Integrin (4)

Interleukin Related (1)

Leukotriene Receptor (5)

MAP4K (1)

Mitochondrial Metabolism (1)

MMP (2)

MyD88 (1)

Na+/H+ Exchanger (NHE) (2)

NF-κB (5)

NO Synthase (4)

NOD-like Receptor (NLR) (1)

Opioid Receptor (1)

p38 MAPK (2)

PARP (4)

Phosphodiesterase (PDE) (1)

PKC (2)

Potassium Channel (2)

Prostaglandin Receptor (3)

Protease Activated Receptor (PAR) (2)

Reactive Oxygen Species (3)

Reverse Transcriptase (1)

RIP kinase (1)

SARS-CoV (4)

Sigma Receptor (2)

Sirtuin (1)

Telomerase (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

TRP Channel (2)

Tyrosinase (1)

Urotensin Receptor (2)

VEGFR (1)

α-synuclein (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (63)

Endocrinology (2)

Infection (5)

Inflammation/Immunology (35)

Metabolic Disease (6)

Neurological Disease (17)

106

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas

HY-101205

ICI 199441
Opioid Receptor Cardiovascular Disease

ICI 199441 is a potent and selective κ-opioid receptor agonist. ICI 199441 can improve heart resistance to ischemia/reperfusion.

ICI 199441	Opioid Receptor	Cardiovascular Disease
ICI 199441 is a potent and selective κ-opioid receptor agonist. ICI 199441 can improve heart resistance to ischemia/reperfusion.

HY-118960

BMS-199264 hydrochloride	ATP Synthase	Cardiovascular Disease
BMS-199264 hydrochloride is an inhibitor of F1F0 ATP hydrolase (IC₅₀=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 hydrochloride selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 hydrochloride also enhances the recovery of contractile function following reperfusion.

HY-W006566

5-AIQ 5-Aminoisoquinolin-1-one	PARP	Cancer
5-AIQ (5-Aminoisoquinolin-1-one) is a water-soluble PARP-1 inhibitor. 5-AIQ is an important functional group in various drugs. 5-AIQ reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver.

HY-W011082

NLRP3-IN-2	NOD-like Receptor (NLR)	Cardiovascular Disease
NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism.

HY-P1010

Z-LEHD-FMK	Caspase Apoptosis	Cancer Neurological Disease
Z-LEHD-FMK is a selective and irreversible inhibitor of caspase-9, protects against lethal reperfusion injury and attenuates apoptosis. Z-LEHD-FMK exhibits the neuroprotective effect in a rat model of spinal cord trauma.

HY-P1010A

Z-LEHD-FMK TFA	Caspase Apoptosis	Cancer Neurological Disease
Z-LEHD-FMK TFA is a selective and irreversible inhibitor of caspase-9, protects against lethal reperfusion injury and attenuates apoptosis. Z-LEHD-FMK TFA exhibits the neuroprotective effect in a rat model of spinal cord trauma.

HY-14290

Pinacidil P-1134	Potassium Channel	Cardiovascular Disease
Pinacidil is a potent activator of potassium channel. Pinacidil is an antihypertensive agent which hyperpolarises vascular smooth muscle by opening K⁺-channels. Pinacidil significantly improves the reperfusion function and cardiac compliance. Pinacidil has direct cardioprotective efficacy.

HY-111475

*Mitochondrial fusion* promoter M1**	Mitochondrial Metabolism	Cardiovascular Disease
Mitochondrial fusion promoter M1 is a mitochondrial dynamic modulator. Mitochondrial fusion promoter M1 preserves the mitochondrial function and promotes cellular respiration. Mitochondrial fusion promoter M1 alleviates cardiac and brain damage in rats with cardiac ischemia/reperfusion injury.

HY-10915

LUF6096	Adenosine Receptor	Cardiovascular Disease
LUF6096, a potent allosteric enhancer of the adenosine A3 receptor, is able to allosterically enhance agonist binding. LUF6096 shows low orthosteric affinity for any of the adenosine receptors. LUF6096 shows protective effects in myocardial ischemia/reperfusion injury.

HY-131041

Ned-K	Calcium Channel	Cardiovascular Disease
Ned-K is a nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist. Ned-K is effective at dampening simulated ischaemia and reperfusion (sIR)-induced Ca²⁺ oscillations in cardiomyocytes.

HY-142059

PDE5-IN-4	Phosphodiesterase (PDE)	Metabolic Disease Cardiovascular Disease
PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure.

HY-139397

TJ-M2010-5	MyD88	Cardiovascular Disease
TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway. TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI).

HY-P99765

Odulimomab anti-LFA1	Integrin	Inflammation/Immunology
Odulimomab (anti-LFA1) is an anti-LFA-1 monoclonal antibody. Odulimomab inhibits proliferation of T lymphocyte and shows protective effects against ischemia and reperfusion injury. Odulimomab can be used for the research of transplant rejection and immunological disease.

HY-152086

DRP1i27	Dynamin	Cardiovascular Disease
DRP1i27 is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury.

HY-148475

NF-κB-IN-7	NF-κB	Cancer Infection Metabolic Disease Inflammation/Immunology Cardiovascular Disease
NF-κB-IN-7 (compound 1B) is a potent NF-κB inhibitor. NF-κB-IN-7 can be used for the research of cancer, inflammation, autoimmune diseases, diabetes and diabetes complications, infections, cardiovascular disease and defective reperfusion injury.

HY-114671

Taprostene CG-4203	Prostaglandin Receptor	Cardiovascular Disease
Taprostene (CG-4203) is a synthetic, chemically stable analogue of Prostacyclin (PGI2). Taprostene exhibits endothelium and myocardial protecting actions after acute myocardial ischemia and reperfusion in cats. Taprostene enhances cytoprotective actions, while minimizing unwanted hemodynamic effects.

HY-130272

Anti-MI/R injury agent 1	Others	Cardiovascular Disease
Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats.

HY-W033577

Tricarbonyldichlororuthenium(II) dimer CORM-2	Others	Inflammation/Immunology
Tricarbonyldichlororuthenium(II) dimer is a pharmacological donor of CO releasing. CO releases from Tricarbonyldichlororuthenium(II) dimer prevents gastric mucosal oxidative damage induced by ischemia/reperfusion (I/R) improving gastric blood flow (GBF), decreasing DNA oxidation and inflammatory response on systemic level.

HY-N5057

Przewalskinic acid A	Others	Cardiovascular Disease
Przewalskinic acid A is a phenolic acid found in the Salvia przewalskii Maxim herb. Phenolic acids show potent antioxidant activities and potential effects in protecting against brain and heart damage caused by ischemia reperfusion.

HY-101200

Linsidomine hydrochloride SIN-1 chloride	Drug Metabolite	Cardiovascular Disease
SIN-1 (chloride) is the active metabolite of molsidomine. SIN-1 (chloride) exhibits potent vasorelaxant effect and inhibition of platelet aggregation. SIN-1 (chloride) decreases myocardial necrosis and reperfusion-induced endothelial dysfunction in models of myocardial ischemia-reperfusion.

HY-N6634

Araloside C
Others Others

Araloside C exhibits protective effects against myocardial ischaemia/reperfusion injury.

Araloside C	Others	Others
Araloside C exhibits protective effects against myocardial ischaemia/reperfusion injury.

HY-138454

MEG hemisulfate Mercaptoethylguanidine hemisulfate	NO Synthase	Inflammation/Immunology
MEG (Mercaptoethylguanidine) hemisulfate is a potent and selective inhibitor of the inducible NO synthase (iNOS), with EC₅₀s of 11.5, 110, and 60 μM for iNOS, ecNOS, and bNOS respectively in tissue homogenates. MEG hemisulfate is also a potent scavenger of peroxynitrite and inhibits peroxynitrite-induced oxidative processes. MEG hemisulfate has a protective effect in many experimental models of inflammation, including ischemia/reperfusion injury, periodontitis, hemorrhagic shock, inflammatory bowel disease, and endotoxic and septic shock.

HY-107526

(Rac)-ALX 5407 (Rac)-NFPS	GlyT	Neurological Disease
NFPS is a selective, non-competitive glycine transporter-1 (GlyT1) inhibitor with IC₅₀s of 2.8 nM and 9.8 nM for hGlyT1 and rGlyT1, respectively. NFPS exerts neuroprotection via glyR alpha1 subunit in the rat model of transient focal cerebral ischaemia and reperfusion.

HY-141625

TRC160334
HIF/HIF Prolyl-Hydroxylase Others

TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury.

TRC160334	HIF/HIF Prolyl-Hydroxylase	Others
TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury.

HY-W015061

Phenylacetylglycine	Adrenergic Receptor Apoptosis Endogenous Metabolite	Metabolic Disease Cardiovascular Disease
Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion.

HY-B0079

Sugammadex sodium Org25969	Others	Neurological Disease Cardiovascular Disease
Sugammadex sodium is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex sodium shows nephroprotective effect in ischemia-reperfusion injury.

HY-B0079A

Sugammadex Org25969 free acid	Others	Neurological Disease Cardiovascular Disease
Sugammadex is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex shows nephroprotective effect in ischemia-reperfusion injury.

HY-108564

L 655240	Prostaglandin Receptor	Cardiovascular Disease
L 655240 is thromboxane antagonist. L 655240 attenuates early ischemia- and reperfusion-induced arrhythmias in a canine model of coronary artery occlusion. L 655240 also involves in cancer and autoimmune disorders.

HY-12022

3-Aminobenzamide PARP-IN-1	PARP	Cancer
3-Aminobenzamide (PARP-IN-1) is a potent inhibitor of PARP with IC₅₀ of appr 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.

HY-N2014

Verbenalin	SARS-CoV	Infection Inflammation/Immunology
Verbenalin is Verbena glycoside, with anti-inflammatory, anti-fungal anti-virus activities. Verbenalin can be used for the research of prostatitis. Verbenalin can reduce cerebral ischemia-reperfusion injury.

HY-117243

GSK329	Others	Cardiovascular Disease
GSK329 is a potent and selective diarylurea inhibitor of the cardiac-specific kinase TNNI3K. GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury.

HY-108457

9-Phenanthrol 9-Hydroxyphenanthrene; NSC 50554	TRP Channel	Cardiovascular Disease
9-Phenanthrol (9-Hydroxyphenanthrene) is a potent and selective human TRPM4 inhibitor, with an IC₅₀ of 20 μM. 9-Phenanthrol can be used for the research of ischemia-reperfusion injury.

HY-136744

Caspase-9 Inhibitor III Ac-LEHD-cmk	Caspase	Cardiovascular Disease
Caspase-9 Inhibitor III (Ac-LEHD-cmk) is a caspase-9 inhibitor. Caspase-9 Inhibitor III exhibits protective effects on ischemia-reperfusion-induced myocardial injury.

HY-E70008

Lumbokinase capsules	Sirtuin	Inflammation/Immunology
Lumbokinase capsules attenuates myocardial ischemia-reperfusion (I-R) injury through the activation of Sirt1 signaling, and thus enhances autophagic flux and reduces I-R-induced oxidative damage, inflammation and apoptosis.

HY-121018

Daltroban BM-13505; SKF 96148	Prostaglandin Receptor	Cardiovascular Disease
Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury.

HY-129997

Luteolinidin chloride	CD38	Inflammation/Immunology
Luteolinidin is a natural deoxyanthocyanidin, isolated from Sorghum bicolor . Luteolinidin is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.

HY-17443

Sivelestat EI546; LY544349; ONO5046	Elastase SARS-CoV	Cancer
Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC₅₀ of 44 nM and a K_i of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.

HY-17443A

Sivelestat sodium ONO5046-Na; Sodium sivelestat; EI546 sodium; LY544349 sodium	Elastase SARS-CoV	Cancer
Sivelestat (EI546) sodium is a competitive inhibitor of human neutrophil elastase, with an IC₅₀ of 44 nM and a K_i of 200 nM. Sivelestat (EI546) sodium has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.

HY-107394

UK 356618	MMP	Cancer Inflammation/Immunology
UK 356618 (Compound 4j) is a potent and selective inhibitor of matrix metalloprotease-3 (MMP-3) with an IC₅₀ of 5.9 nM. UK 356618 is less potent against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14 compared with MMP-3.

HY-17443B

Sivelestat sodium tetrahydrate EI546 sodium tetrahydrate; LY544349 sodium tetrahydrate; ONO5046 sodium tetrahydrate	Elastase SARS-CoV	Cancer
Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC₅₀ of 44 nM and a K_i of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.

HY-B1409

Isosorbide dinitrate ISDN	NO Synthase	Cardiovascular Disease
Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI).

HY-W015061S

N-(Phenylacetyl-d5)glycine 2-(2-Phenylacetamido)acetic acid-d₅	Adrenergic Receptor Apoptosis Endogenous Metabolite	Cardiovascular Disease
N-(Phenylacetyl-d₅)glycine is the deuterium labeled Phenylacetylglycine. Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion[1][2].

HY-122935

Nigranoic acid	HIV Reverse Transcriptase	Infection
Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits HIV-1 reverse transcriptase. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model.

HY-106262B

Delcasertib hydrochloride KAI-9803 hydrochloride; BMS-875944 hydrochloride	PKC	Inflammation/Immunology Cardiovascular Disease
Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).

HY-132845

Utreloxastat PTC857	α-synuclein	Neurological Disease
Utreloxastat (PTC857) is a compound used for the research of the disorders including α-synucleinopathies, tauopathies, Amyotrophic lateral sclerosis (ALS), traumatic brain injury, and ischemic-reperfusion related injuries (patent WO2020081879A2, example A1).

HY-106262

Delcasertib KAI-9803; BMS-875944	PKC	Inflammation/Immunology Cardiovascular Disease
Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).

HY-131370

Intralipid	Others	Cancer Inflammation/Immunology
Intralipid is a safe fat emulsion that can be used as a nutritional supplement. Intralipid effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response.

HY-131370A

Intralipid 10%	Others	Cancer Inflammation/Immunology
Intralipid 10% is a safe fat emulsion that can be used as a nutritional supplement. Intralipid 10% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response.

HY-131370B

Intralipid 20%	Others	Cancer
Intralipid 20% is a safe fat emulsion that can be used as a nutritional supplement. Intralipid 20% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response.

HY-134266

8-Bromo-AMP 8-Bromoadenosine 5'-monophosphate; 8-Bromoadenylic acid	Others	Cardiovascular Disease
8-Bromo-AMP (8-Bromoadenosine 5'-monophosphate) is a membrane permeable cAMP analogue. 8-Bromo-AMP can improve the ability of the heart to recover from ischemia and reperfusion by increasing the levels of ATP, ADP, and total adenine nucleotides.

HY-A0119

Nitroprusside disodium dihydrate Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate	Autophagy	Cardiovascular Disease Cancer
Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) is a vasodilator that available for the research of acute hypertension, heart failure. Nitroprusside disodium dehydrate induces autophagy in glutathione-depleted osteoblasts. Nitroprusside disodium dehydrate acts as a nitric oxide (NO) donor in a rat intestinal ischemia reperfusion model.

HY-108448

N-Oleoyldopamine OLDA	TRP Channel	Cardiovascular Disease
N-Oleoyldopamine (OLDA) is a product of condensation of oleic acid and dopamine (DA) and an endogenous TRPV1 selective agonist. N-Oleoyldopamine (OLDA) can crosses the blood-brain barrier. N-oleoyl-dopamine protects the heart against ischemia-reperfusion injury via activation of TRPV1.

HY-N2638

Ilexsaponin A	Apoptosis	Cardiovascular Disease
Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes.

HY-125773

β-cyano-L-Alanine Beta-cyano-l-alanine	Endogenous Metabolite	Neurological Disease
β-cyano-L-Alanine (Beta-cyano-l-alanine), a nitrile of widespread occurrence in higher plants, is enzymatically produced by cyanoalanine synthase from cyanide and cysteine as substrates. β-cyano-L-Alanine abolishes the protective effect of ethanol on cerebral ischemia/reperfusion (I/R) injury.

HY-13315S1

Montelukast-d6 sodium MK0476-d₆	Leukotriene Receptor	Inflammation/Immunology
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-P1098

Ac2-26	NF-κB	Inflammation/Immunology
Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.

HY-13315S

Montelukast-d6 MK0476-d6 (free acid)	Leukotriene Receptor	Inflammation/Immunology
Montelukast-d₆ is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-N0745

Senkyunolide I	Caspase	Inflammation/Immunology
Senkyunolide I, isolated from Ligusticum chuanxiong Hort, is an anti-migraine compound. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3.

HY-132280

Tirilazad U 74006F free base	Antibiotic	Infection Neurological Disease
Tirilazad is a nonglucocorticoid, 21-aminosteroid that inhibits lipid peroxidation. Tirilazad can attenuate brain or spinal cord injury caused by trauma, stroke, ischemia and reperfusion injury. Tirilazad has antiviral activities against nCoV. Tirilazad is neuroprotective for ischaemic stroke, can be used for subarachnoid hemorrhage research.

HY-10655A

Palosuran hydrochloride ACT-058362 hydrochloride	Urotensin Receptor	Cardiovascular Disease
Palosuran hydrochloride (ACT-058362 hydrochloride) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC₅₀ of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran hydrochloride can improves pancreatic and renal function in diabetic rats.

HY-101016

17-ODYA	Cytochrome P450 Apoptosis	Cardiovascular Disease
17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC₅₀<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes.

HY-N1485

Cycloastragenol Astramembrangenin; Cyclosieversigenin	Telomerase	Inflammation/Immunology Neurological Disease
Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties.

HY-10655

Palosuran ACT-058362	Urotensin Receptor	Cardiovascular Disease
Palosuran (ACT-058362) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC₅₀ of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran can improves pancreatic and renal function in diabetic rats.

HY-119152

CMX-2043	Insulin Receptor Tyrosinase Akt	Others
CMX-2043 is a novel analogue of α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model.

HY-P1098A

Ac2-26 TFA	NF-κB	Inflammation/Immunology
Ac2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.

HY-18754

FR 167653 free base	p38 MAPK Autophagy	Endocrinology
FR 167653 free base, an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 free base is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo.

HY-103346

MMPSI	Caspase Apoptosis	Cardiovascular Disease
MMPSI is a potent and selective small molecule caspase 3 and caspase 7 inhibitor with an IC₅₀ of 1.7 μM for human caspase-3. MMPSI can significantly reduce ischemia-reperfusion-induced infarct size in the isolated rabbit heart, and reduce apoptosis in both the ischemic myocardium and isolated cardiomyocytes. MMPSI can be used for researching cardioprotection.

HY-135430

SRS16-86	Ferroptosis	Inflammation/Immunology
SRS16-86 is a potent inhibitor of ferroptosis. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research.

HY-118530

Bucillamine SA96; Thiobutarit	VEGFR	Inflammation/Immunology Cardiovascular Disease
Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA).

HY-106592A

U-74389G PNU74389G (meleate)	Others	Others
U-74389G (PNU74389G meleate) is an antioxidant, can inhibit lipid peroxidation reactions. U-74389G can protect against ischemia-reperfusion injury and be widely used in animal models of ischemic injury and hypertension. U-74389G shows anti-inflammatory activity.

HY-18754A

FR 167653 FR 167653 sulfate	p38 MAPK Autophagy	Endocrinology
FR 167653 (FR 167653 sulfate), an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 (FR 167653 sulfate) is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo.

HY-103445

SSR69071	Elastase	Cardiovascular Disease
SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury. SSR69071 displays a higher affinity for human elastase (K_i=0.0168 nM) than for rat (K_i=3 nM), mouse (K_i=1.8 nM), and rabbit (K_i= 58 nM) elastases.

HY-107571

VULM 1457	Acyltransferase	Metabolic Disease Cardiovascular Disease
VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia.

HY-P99886

Pexelizumab h5G1. 1-SC	Complement System Apoptosis	Neurological Disease Cardiovascular Disease
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction.

HY-P3868A

QEQLERALNSS TFA	Apoptosis	Cardiovascular Disease
QEQLERALNSS TFA is a helix B surface peptide (HBSP) derived from erythropoietin with tissue protective activities. QEQLERALNSS TFA protects cardiomyocytes from apoptosis.

HY-135953

CDDO-3P-Im	Apoptosis	Cancer
CDDO-3P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-3P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model. CDDO-3P-Im is a orally active necroptosis inhibitor that can be used for the research of ischemia/reperfusion (I/R).

HY-100594

EUK-134	NF-κB	Cardiovascular Disease
EUK-134, a synthetic superoxide dismutase and catalase mimetic, protects rat kidneys from ischemia-reperfusion-induced damage. EUK-134 is a superoxide dismutase (SOD) mimetics (SODm) with catalase activity. EUK-134 is a mitoprotective antioxidant. EUK-134 reduces the expression of NF-κB, MDA level, and protein carbonylation in H9C2 cells.

HY-17369B

Tirofiban L700462; MK383	Integrin	Cardiovascular Disease
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area.

HY-18100A

PRE-084 hydrochloride	Sigma Receptor Akt NO Synthase	Neurological Disease Cardiovascular Disease
PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC₅₀ of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway.

HY-17369A

Tirofiban hydrochloride L700462 hydrochloride; MK383 hydrochloride	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area.

HY-18100

PRE-084	Sigma Receptor Akt NO Synthase	Neurological Disease Cardiovascular Disease
PRE-084 is a highly selective σ1 receptor (S1R) agonist, with an IC₅₀ of 44 nM. PRE-084 exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway.

HY-17369

Tirofiban hydrochloride monohydrate L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area.

HY-13315

Montelukast sodium MK0476	Leukotriene Receptor	Inflammation/Immunology
Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research.

HY-126124

AP39	Others	Neurological Disease Cardiovascular Disease
AP39 is a triphenylphosphonium derivatised anethole dithiolethione and mitochondria-targeting hydrogen sulfide (H₂S) donor. AP39 increases intracellular H₂S levels. AP39 exerts cytoprotective effects and maintains mitochondrial DNA integrity under oxidative stress conditions. AP39 protects against myocardial reperfusion injury in mice model and has the potential for Alzheimer's disease research.

HY-151369

AV123	RIP kinase	Metabolic Disease Inflammation/Immunology Neurological Disease Cardiovascular Disease
AV123 (compound 12) is a non-cytotoxic RIPK1 inhibitor (IC₅₀=12.12 µM). AV123 blocks the TNF-α-induced necroptotic (EC₅₀=1.7 μM) but not the apoptotic cell death. AV123 can be used in the study of necrotic chronic conditions such as ischemia-reperfusion injury of the brain, heart and kidney, inflammatory diseases, neurodegenerative diseases and infectious diseases.

HY-106139

Bimosiamose TBC-1269	Others	Inflammation/Immunology
Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC₅₀s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose has anti-inflammatory effects.

HY-106139A

Bimosiamose disodium TBC-1269Z	Others	Inflammation/Immunology
Bimosiamose disodium (TBC-1269Z) is a nonoligosaccharide pan-selectin inhibitor with IC₅₀s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose disodium has anti-inflammatory effects.

HY-103331

COR170	Cannabinoid Receptor	Inflammation/Immunology Neurological Disease
COR170 (11u) is a selective CB2 inverse-agonist which is a 4-quinolone-3-carboxylic acid derivative with a K_i value of 3.8 nM for CB2 receptor. COR170 can be used for the research of inflammation and neuroprotection.

HY-108467

GGsTop Nahlsgen	Others	Cardiovascular Disease
GGsTop (Nahlsgen) is a potent, non-toxic, highly selective and irreversible γ−glutamyl transpeptidase (GGT) inhibitor, with a K_i of 170 μM for Human GGT. GGsTop shows a pK_a of 9.71, also exhibits K_ons of 150±10 and 51±3 M^-1 s^-1 against E.coli GGT and human GGT, respectively. GGsTop protects hepatic ischemia-reperfusion injury in rat model.

HY-13315A

Montelukast MK0476 free base	Leukotriene Receptor	Inflammation/Immunology
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research.

HY-N0615

Notoginsenoside R1 Sanchinoside R1; Sanqi glucoside R1	Amyloid-β Apoptosis	Others
Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H₂O₂-induced oxidative damage in PC12 cells.

HY-13315B

Montelukast dicyclohexylamine MK0476 dicyclohexylamine	Leukotriene Receptor	Inflammation/Immunology
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research.

HY-15046

EB-47	PARP	Inflammation/Immunology Cardiovascular Disease
EB-47, a potent and selective PARP-1/ARTD-1 inhibitor with an IC₅₀ value of 45 nM, shows modest potency against ARTD5 with an IC₅₀ value of 410 nM. EB-47 mimics the substrate NAD⁺ and extends from the nicotinamide to the adenosine subsite.

HY-108631

EB-47 dihydrochloride	PARP	Inflammation/Immunology
EB-47 dihydrochloride, a potent and selective PARP-1/ARTD-1 inhibitor with an IC₅₀ value of 45 nM, shows modest potency against ARTD5 with an IC₅₀ value of 410 nM. EB-47 mimics the substrate NAD⁺ and extends from the nicotinamide to the adenosine subsite.

HY-121166

Levobetaxolol (S)-Betaxolol	Adrenergic Receptor	Others
Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC₅₀ values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure). Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma.

HY-111754

DMX-5804	MAP4K	Cardiovascular Disease
DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC₅₀ of 3 nM, a pIC₅₀ of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC₅₀, 8.18), and TNIK/MAP4K7 (pIC₅₀, 7.96). DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice.

HY-18071A

BI-9627 hydrochloride	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury.

HY-N0408

Picroside II	NF-κB Reactive Oxygen Species Apoptosis Influenza Virus	Cancer Infection Inflammation/Immunology Neurological Disease
Picroside II, an iridoid compound extracted from Picrorhiza, exhibits anti-inflammatory and anti-apoptotic activities. picroside II alleviates the inflammatory response in sepsis and enhances immune function by inhibiting the activation of NLRP3 inflammasome and NF-κB pathways. Picroside II is an antioxidant, exhibits a significant neuroprotective effect through reducing ROS production and protects the blood-brain barrier (BBB) after cerebral ischemia-reperfusion (CI/R) injury. Picroside II has antioxidant, anti-inflammatory, immune regulatory, anti-virus and other pharmacological activities.

HY-18071

BI-9627	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC₅₀s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury.

HY-117970

MMPI-1154	MMP	Cardiovascular Disease
MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC₅₀=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC₅₀s of 1.8 μM,10 μM, and 13 μM, respectively.

HY-124750

NecroX-7	TNF Receptor Interleukin Related Toll-like Receptor (TLR) Reactive Oxygen Species	Inflammation/Immunology Cardiovascular Disease
NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research.

HY-14993

SCH79797	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes.

HY-14994

SCH79797 dihydrochloride	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes.

HY-126653

Atpenin A5	Potassium Channel	Cardiovascular Disease
Atpenin A5 is a potent and highly specific complex II inhibitor (IC₅₀ ~10 nM), and is an effective mK_ATP channel agonist and cardioprotective agent.

HY-N7627

Regaloside C	Others	Inflammation/Immunology Cardiovascular Disease
Regaloside C is a glycerol glucoside isolated from the bulbs of Lilium genus with anti-inflammatory activities. Regaloside C has cardiomyocyte protective activity by protecting the mitochondria in H₂O₂-induced heart H9C2 cells.

HY-129460

XJB-5-131	Reactive Oxygen Species	Neurological Disease
XJB-5-131 is a mitochondria-targeted ROS and electron scavenger. XJB-5-131 is a bi-functional antioxidant that comprises a radical scavenger. XJB-5-131 is a synthetic antioxidant that targets mitochondria. XJB-5-131 is an effective ionizing irradiation protector and mitigator of cord blood mononuclear cells (CB MNCs).

Cat. No.	Product Name	Type

HY-P2824

Streptokinase	Enzyme
Streptokinase is a bacteria-derived protein and a plasminogen activator. Streptokinase is widely used for the research of the blood-clotting disorders. Streptokinase improves reperfusion blood flow after coronary artery occlusion.